Serum miR-206 and miR-132 as Potential Circulating Biomarkers for Mild Cognitive Impairment

Area of Science:

• Biochemistry and Molecular Biology
• Neuroscience
• Biomarker Discovery

Background:

• MicroRNAs (miRNAs) are small, non-coding RNAs regulating gene expression and implicated in disease pathogenesis.
• Circulating miRNAs in bodily fluids are emerging as potential diagnostic biomarkers for various pathological conditions.
• Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia, necessitating reliable diagnostic tools.

Purpose of the Study:

• To investigate the potential of circulating miRNAs as diagnostic biomarkers for mild cognitive impairment (MCI).
• To evaluate the diagnostic performance of specific miRNAs, including miR-206 and miR-132, in serum samples from MCI patients.

Main Methods:

• Serum samples were collected from 66 patients with MCI and 76 normal controls.
• Seven Alzheimer's disease-related miRNAs were quantified using quantitative real-time PCR (qRT-PCR).
• Diagnostic performance was assessed using receiver operating characteristic (ROC) curves and area under the curve (AUC) analysis.

Main Results:

• Serum levels of miR-206 and miR-132 were significantly elevated in MCI patients compared to normal controls.
• A combination of miR-206 and miR-132 achieved a high diagnostic AUC of 0.981.
• Individual miRNAs also showed diagnostic potential: miR-206 (AUC = 0.880) and miR-132 (AUC = 0.912).
• miR-206 and miR-132 levels correlated with Montreal Cognitive Assessment scores in MCI patients.

Conclusions:

• Circulating miR-206 and miR-132 are upregulated in patients with mild cognitive impairment.
• These miRNAs demonstrate potential as novel, non-invasive biomarkers for the diagnosis of MCI.
• Further validation is warranted to establish their clinical utility in diagnosing MCI.